Adaptive Biotechnologies (ADPT) Income from Non-Controlling Interests (2021 - 2026)
Adaptive Biotechnologies' (ADPT) quarterly Income from Non-Controlling Interests came in at $18000.0 in Q1 2026, down 18.18% year-on-year from $22000.0 in Q1 2025, and up 1900.0% quarter-over-quarter from -$1000.0 in Q3 2025.
Adaptive Biotechnologies (ADPT) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Adaptive Biotechnologies has disclosed Income from Non-Controlling Interests across 6 years of filings, most recently posting $18000.0 for Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at $18000.0, down 18.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $38000.0 (up 169.09% YoY), and the FY2025 annual result was $42000.0, up 140.78% from the prior year.
- Income from Non-Controlling Interests came in at $18000.0 for Q1 2026 at Adaptive Biotechnologies, up from -$1000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $22000.0 in Q1 2025 to a low of -$60000.0 in Q1 2022.
- The 5-year median for Income from Non-Controlling Interests is -$26000.0 (2023), against an average of -$17125.0.
- Across the five-year window, Income from Non-Controlling Interests tumbled 2500.0% in 2024 and jumped 184.62% in 2025, its largest moves.
- Adaptive Biotechnologies' Income from Non-Controlling Interests stood at -$41000.0 in 2022, then jumped by 36.59% to -$26000.0 in 2023, then rose by 3.85% to -$25000.0 in 2024, then surged by 96.0% to -$1000.0 in 2025, then surged by 1900.0% to $18000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at $18000.0 (Q1 2026), -$1000.0 (Q3 2025), and $21000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 29,902.70 Bn | 29,902.24 Bn | 1.11 Bn | - |
| 2 | Thermo Fisher Scientific | 175.99 Bn | 172.74 Bn | 7.74 Bn | 5.00 Mn |
| 3 | Danaher | 129.87 Bn | 124.18 Bn | 3.59 Bn | - |
| 4 | Idexx Laboratories | 44.75 Bn | 44.55 Bn | 722.74 Mn | - |
| 5 | Agilent Technologies | 37.52 Bn | 35.72 Bn | 990.00 Mn | - |
| 6 | Iqvia Holdings | 30.91 Bn | 28.94 Bn | 1.36 Bn | 1.00 Mn |
| 7 | Natera | 30.21 Bn | 29.11 Bn | 696.04 Mn | - |
| 8 | Illumina | 24.19 Bn | 23.04 Bn | 721.00 Mn | - |
| 9 | Mettler Toledo International | 23.12 Bn | 23.06 Bn | 555.82 Mn | - |
| 10 | Adaptive Biotechnologies | 2.60 Bn | 2.39 Bn | 52.17 Mn | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | -26,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Sep 30, 2023 | -26,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Dec 31, 2022 | -41,000.00 |
| Sep 30, 2022 | -38,000.00 |
| Jun 30, 2022 | -38,000.00 |
| Mar 31, 2022 | -60,000.00 |
| Dec 31, 2021 | 76,000.00 |
| Sep 30, 2021 | -95,000.00 |